Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396246 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 2±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396246 | |||
n/a | |||
Name | BDBM50396246 | ||
Synonyms: | CHEMBL2172305 | ||
Type | Small organic molecule | ||
Emp. Form. | C31H38FN5O4 | ||
Mol. Mass. | 563.6629 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(O)=O)cc12 |r,wU:9.12,6.5,(45.25,-54.5,;43.75,-54.18,;43.27,-52.72,;42.72,-55.33,;41.21,-55.01,;40.18,-56.15,;40.73,-53.54,;39.23,-53.23,;38.75,-51.77,;39.78,-50.62,;41.28,-50.93,;41.76,-52.4,;39.3,-49.16,;40.2,-47.9,;41.74,-47.89,;42.5,-46.55,;41.72,-45.23,;44.04,-46.55,;44.82,-47.87,;46.35,-47.87,;47.12,-46.53,;48.66,-46.51,;46.33,-45.19,;44.8,-45.21,;39.28,-46.65,;37.81,-47.14,;36.47,-46.38,;35.14,-47.15,;35.14,-48.69,;33.81,-49.46,;32.47,-48.69,;32.47,-47.15,;31.15,-46.38,;29.81,-47.14,;29.81,-48.68,;31.14,-49.46,;28.48,-46.36,;28.48,-44.82,;27.14,-47.13,;36.48,-49.46,;37.82,-48.69,)| | ||
Structure |